NIOX NIOX (formerly Circassia) is a specialty biopharmaceutical company focused on developing novel immunotherapies | ![]() Affimed N.V. Affimed is a NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. | |||
Founding Date | Founding Date 2011 | Founding Date 2006 | Founding Date 2000 | Founding Date 1948 |
Type | Type Private | Type Public | Type Public | Type Subsidiary |
Tags | ||||
Locations | Locations San Francisco, US HQ | Locations Morrisville, US HQ Bad Homburg Vor Der Höhe, DE Uppsala, SE Morrisville, US | Locations Heidelberg, DE HQ | |
Employees | Employees 1 | Employees 91 | Employees 76 | Employees 650 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 340.9 m | Valuation ($) 52.5 m | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) £48.7m (FY, 2025) | Revenue (est.) €8.3m (FY, 2023) | Revenue (est.) £731.3m (FY, 2019) |
Cost of goods | Cost of goods N/A | Cost of goods £11.1m (FY, 2025) | Cost of goods N/A | Cost of goods £221m (FY, 2019) |
Gross profit | Gross profit N/A | Gross profit £38.2m (FY, 2025) | Gross profit €13m (FY, 2023) | Gross profit £510.3m (FY, 2019) |
Net income | Net income N/A | Net income £7m (FY, 2025) | Net income (€105.9m) (FY, 2023) | Net income £88.3m (FY, 2019) |
Funding | ||||
Total funding raised | Total funding raised $ 2.2m | Total funding raised $ 122.8m | Total funding raised N/A | Total funding raised N/A |
NIOX (formerly Circassia) is a specialty biopharmaceutical company focused on developing novel immunotherapies
View company
Affimed is a NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies.
View company